Company description

EpiVax is a biotechnology company headquartered in Providence, Rhode Island, focused on computational immunology and immunogenicity assessment for biologics, vaccines and peptide therapeutics. Founded in 1998, the company has more than 25 years of experience supporting pharmaceutical and biotechnology organisations in developing safer and more effective therapies.

The company applies proprietary immunoinformatics tools, in vitro assays and consulting expertise to predict and mitigate immune responses during drug development. These capabilities help sponsors identify potential immunogenicity risks early, optimise biologic sequences and improve clinical success rates.

EpiVax partners with global pharmaceutical companies, biotechnology firms, government agencies and academic institutions. Its integrated approach combines computational modelling, laboratory validation and regulatory consulting to support preclinical and early clinical development of biologics and vaccines.

The company has also developed multiple proprietary platforms and technologies designed to accelerate vaccine design, immune modulation and therapeutic optimisation. These tools enable rapid assessment of immunogenicity and support the development of next-generation biologics and immunotherapies.

In April 2026, EpiVax was acquired by SV Health Investors, with plans to expand computational tools, cell-based assays and analytical consulting capabilities as part of its next growth phase.

Key products and services

Immunogenicity risk assessment

• Preclinical immunogenicity prediction for biologics and peptides
• Anti-drug antibody (ADA) risk assessment
• Sequence optimisation and de-risking strategies

Computational immunology platforms

• ISPRI™ immunogenicity screening platform
• iVAX™ vaccine design toolkit
• EpiMatrix®, JanusMatrix® and related predictive algorithms

Vaccine design and immunotherapy development

• Epitope identification and vaccine optimisation
• Immune modulation strategies
• Rapid vaccine design and development support

In vitro immunology services

• HLA binding assays
• Human T-cell assays
• Immunogenicity validation studies

Consulting and regulatory support

• Immunogenicity strategy consulting
• Preclinical development advisory
• Regulatory risk mitigation support

By combining computational immunology, laboratory validation and strategic consulting, EpiVax helps pharmaceutical and biotechnology companies reduce immunogenicity risk and accelerate biologic and vaccine development. Its proprietary technology platforms, long-standing scientific expertise and global client base position the company as a specialist CRO in immunogenicity assessment and immune-based therapeutic development.